Loading...
Loading...
NVIV| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 72.0K |
| Gross Profit | -72.0K |
| Operating Expense | 2,828.0K |
| Operating I/L | -2,697.0K |
| Other Income/Expense | 1.0K |
| Interest Income | 130.0K |
| Pretax | -2,697.0K |
| Income Tax Expense | -71.0K |
| Net Income/Loss | -2,697.0K |
InVivo Therapeutics Holdings Corp. is a biotechnology company specializing in the development and commercialization of biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). Its primary product is the Neuro-Spinal Scaffold implant, a bioresorbable polymer scaffold designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company generates revenue through the development, clinical trials, and potential commercialization of its innovative medical devices aimed at addressing the unmet medical needs of patients with spinal cord injuries.
